<DOC>
	<DOCNO>NCT02283476</DOCNO>
	<brief_summary>Endostar anti-angiogenesis product launch China . The efficacy safety define . However , compliance unsatisfactory since routine i.v Endostar need 3 4 hour daily one cycle 14 day . The continuous intravenous infusion use venous pump improve compliance.The comparative study efficacy safety do concern continuous routine i.v.In addition , patient benefit Endostar investigate . The biological marker , circulate endothelial cells，CECs , explore study .</brief_summary>
	<brief_title>The Comparative Study Rh-Endostatin ( Endostar® ) Continuous Intravenous Infusion Routine i.v Combination With GP Regimens Phase III B/IV Squamous Cell Lung Cancer Biological Markers Exploration .</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1. primary lung squamous carcinoma confirm cytology histology , exclude sputum examination . 2. phase IIIB /IV base IASLC 2009 TNM criterion . 3. least one measurable tumor base RECIST 1.1 ( long diameter : ≥20 mm CT scan 10 mm spiral CT ) 4. male female , age≥18 ≤75 year old 5 . ECOG PS : 0 1 6. estimated time survival : ≥ 3 month 7. suitable hematologic function : ANC≥2×109/L , PLC≥100×109/L Hb≥9 g/dL 8. suitable liver function : Total bilirubin≤normal ULN , AST ALT≤2.5×normal ULN , ALP≤5×normal ULN . 9. suitable renal function : Cr≤normal ULN , Ccr≥60 ml/min 10 . EKG normal 11. without heal wound 12. history anticancer therapy , adjuvant/neoadjuvant chemotherapy nonmetastatic tumor finish 6 month enrolment . 13. female subject productive ability , urine pregnancy test must do negative within 7 day enrolment . 14. history serious allergic biologic agent , especially E.Coli product 15. authorized ICF must sign 1 . Woman pregnancy breastfeeding , productive ability without contraception . 2 . Having serious acute infection uncontrolled purulent/chronic infection unhealed wound . 3 . Having serious heart disease , include congestive heart failure , uncontrolled highrisk arrhythmia , unstable angina , myocardial infarction , valvular disease , refractory hypertension . 4 . Having uncontrolled nervous mental disease low compliance reluctance description response ; uncontrolled primary brain tumor metastatic brain cancer obvious intracranial hypertension mental symptom . 5 . Having tendency bleeding , FIB &lt; 2G/L 6 . Being receive adjuvant chemotherapy . 7 . On condition investigator considers , subject fitful participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>efficacy safety</keyword>
</DOC>